ExecuPharm: PAREXEL International : Announces Execution of Definitive Agreement to Acquire ExecuPharm

(4-traders.com) By a News Reporter-Staff News Editor at Clinical Trials Week -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc. ("ExecuPharm"), a leading, global functional service provider (FSP) serving the...http://www.4-traders.com/PAREXEL-INTERNATIONAL-COR-10548/news/PAREXEL-International-Announces-Execution-of-Definitive-Agreement-to-Acquire-ExecuPharm-23174877/